MUC5B启动子变异与类风湿关节炎相关间质性肺病生存的关联
在退伍军人事务部类风湿关节炎注册队列中,263例类风湿关节炎相关间质性肺病患者中33.5%携带MUC5B rs35705950启动子变异,该变异与总体生存、按间质性肺病模式分层生存及呼吸相关或非呼吸相关死亡原因均无显著关联。
要点
- 在263例类风湿关节炎相关间质性肺病患者中,MUC5B启动子变异患病率为33.5%。
- 携带与不携带MUC5B变异的死亡率分别为12.2/100人年与11.1/100人年。
- MUC5B状态与总体生存无显著关联(aHR 0.97,95%CI 0.68-1.37)。
核心结论
- MUC5B启动子变异与类风湿关节炎相关间质性肺病风险相关,但在本多中心队列中不能预测该类患者的生存。
- 需要进一步研究以识别类风湿关节炎相关间质性肺病的其他遗传和非遗传预后因素,以指导疾病管理。
研究设计与样本
- 研究纳入退伍军人事务部类风湿关节炎注册队列中经证实的间质性肺病诊断参与者,随访至死亡或研究期结束。
- MUC5B rs35705950启动子变异采用Infinium基因分型阵列检测,按常染色体显性遗传模式分析。
- 生存和死亡原因取自退伍军人事务部死亡记录和国家死亡索引。
- 采用Cox回归模型检验MUC5B启动子变异与生存的关联,并校正潜在混杂因素。
主要发现
- 263例类风湿关节炎相关间质性肺病参与者平均年龄69岁,95%为男性,73%为白人,85%有吸烟史。
- MUC5B启动子变异存在于33.5%的参与者中。
- 携带变异者死亡率12.2/100人年(95%CI 9.4-15.8),不携带者死亡率11.1/100人年(95%CI 9.1-13.5)。
- MUC5B状态与总体生存无显著关联(aHR 0.97,95%CI 0.68-1.37)。
- 按间质性肺病模式分层:临床普通型间质性肺炎(UIP)aHR 0.86(95%CI 0.55-1.35),临床非UIP aHR 1.15(95%CI 0.63-2.09)。
局限性
- 原文结论指出需要进一步研究以识别类风湿关节炎相关间质性肺病的其他遗传和非遗传预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to investigate the association between the MUC5B rs35705950 promoter variant and survival in RA-associated interstitial lung disease (RA-ILD). METHODS: We studied participants in the Veteran Affairs Rheumatoid Arthritis (VARA) registry with validated ILD diagnoses. Participants were followed until death or till the end of the study period. The MUC5B rs35705950 promoter variant was measured using an Infinium genotyping array, assuming autosomal dominant inheritance. Survival and cause of death were determined from VA death records and the National Death Index. Associations of the MUC5B promoter variant with survival were tested in Cox regression models, adjusting for potential confounders. RESULTS: Among 263 participants with RA-ILD (mean age 69 years, 95% male, 73% White, 85% smoking history), the MUC5B promoter variant was present in 33.5%. The mortality rate was similar between those with [12.2/100 PY (95% CI: 9.4, 15.8)] and without [11.1/100 PY (95% CI: 9.1, 13.5)] the variant. MUC5B status was not significantly associated with survival overall [aHR 0.97 (95% CI: 0.68, 1.37)] or when stratified by ILD pattern [clinical usual interstitial pneumonia (UIP) aHR 0.86 (95% CI: 0.55, 1.35); clinical non-UIP aHR 1.15 (95% CI: 0.63, 2.09)]. Further, MUC5B status was not significantly associated with respiratory-related [aHR 0.83 (95% CI: 0.42, 1.66)] or non-respiratory causes of death [aHR 1.08 (95% CI: 0.72, 1.62)]. CONCLUSION: While associated with RA-ILD risk, the MUC5B promoter variant was not predictive of survival among RA-ILD patients in this multicentre cohort. Further studies are needed to identify other genetic and non-genetic prognostic factors in RA-ILD to inform disease management.
引用
- Klein J, Wheeler AM, Baker JF, et al. MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2025. PMID: 39504460. doi:10.1093/rheumatology/keae615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。